Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $6.5 million.

  • Ptc Therapeutics' Change in Receivables fell 1612.9% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 12736.55%. This contributed to the annual value of -$1.7 million for FY2024, which is 21254.06% down from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Change in Receivables is $6.5 million, which was down 1612.9% from -$21.9 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Change in Receivables high stood at $47.8 million for Q1 2025, and its period low was -$40.8 million during Q4 2024.
  • Over the past 5 years, Ptc Therapeutics' median Change in Receivables value was $6.5 million (recorded in 2025), while the average stood at $6.6 million.
  • The largest annual percentage gain for Ptc Therapeutics' Change in Receivables in the last 5 years was 116606.99% (2021), contrasted with its biggest fall of 330781.89% (2021).
  • Ptc Therapeutics' Change in Receivables (Quarter) stood at $16.4 million in 2021, then soared by 44.78% to $23.7 million in 2022, then tumbled by 135.23% to -$8.3 million in 2023, then tumbled by 388.27% to -$40.8 million in 2024, then surged by 115.88% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, -$21.9 million for Q2 2025, and $47.8 million during Q1 2025.